$INSM

The Hottest Biotechs of 2026

Twenty FDA approval actions so far in 2026, eight of them inside a sixteen-day window in August. A first-in-class RAS inhibitor that doubled survival in pancreatic cancer, an oral GLP-1 cleared in fifty days, a first gene therapy for GSDIa, and seven AI platforms with nine assets in humans and nothing yet approved.